PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis
- The Rockefeller University, United States
- Memorial Sloan-Kettering Cancer Center, United States
- Cited 2
- Views 1,299
- Annotations
Abstract
Colorectal cancer (CRC) is a major cause of human death. Mortality is primarily due to metastatic organ colonization, with the liver being the primary organ affected. We modeled metastatic CRC (mCRC) liver colonization using patient-derived primary and metastatic tumor xenografts (PDX). Such PDX modeling predicted patient survival outcomes. In vivo selection of multiple PDXs for enhanced metastatic colonization capacity upregulated the gluconeogenic enzyme PCK1, which enhanced liver metastatic hypoxic growth by driving pyrimidine nucleotide biosynthesis under hypoxia. Consistently, highly metastatic tumors upregulated multiple pyrimidine biosynthesis intermediary metabolites. Therapeutic inhibition of the pyrimidine biosynthetic enzyme DHODH with leflunomide substantially impaired CRC liver metastatic colonization and hypoxic growth. Our findings provide a potential mechanistic basis for the epidemiologic association of anti-gluconeogenic drugs with improved CRC metastasis outcomes, reveal the exploitation of a gluconeogenesis enzyme for pyrimidine biosynthesis under hypoxia, and implicate DHODH and PCK1 as metabolic therapeutic targets in colorectal cancer metastatic progression.
Article and author information
Author details
Funding
National Center for Advancing Translational Sciences (UL1 TR001866)
- Norihiro Yamaguchi
- Ethan M Weinberg
Meyer Foundation
- Norihiro Yamaguchi
The Helmsley Charitable trust
- Norihiro Yamaguchi
National Institute of General Medical Sciences (T32GM07739)
- Alexander Nguyen
NIH Office of the Director (T32CA009673-36A1)
- Hani Goodarzi
NIH Office of the Director (1K99CA194077-01)
- Hani Goodarzi
National Cancer Institute (K00CA222986)
- Maria V Liberti
Starr Foundation
- Sohail Tavazoie
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved protocol, The Rockefeller University Institutional Animal Care and Use Committee (protocol 15783-H).
Human subjects: Approval for the study was obtained through the MSKCC Institutional Review Board/Privacy Board (protocol 10-018A), the MSKCC Institutional Animal Care and Use Committee (protocol 04-03-009), The Rockefeller University Institutional Review Board (protocol STA-0681), Written consent was obtained from all human participants who provided samples for patient-derived xenografts.
Reviewing Editor
- William C. Hahn, Dana-Farber Cancer Institue, United States
Publication history
- Received: September 23, 2019
- Accepted: December 15, 2019
- Accepted Manuscript published: December 16, 2019 (version 1)
- Accepted Manuscript updated: December 23, 2019 (version 2)
- Version of Record published: January 24, 2020 (version 3)
Copyright
© 2019, Yamaguchi et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,299
- Page views
-
- 281
- Downloads
-
- 2
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
Downloads (link to download the article as PDF)
Download citations (links to download the citations from this article in formats compatible with various reference manager tools)
Open citations (links to open the citations from this article in various online reference manager services)
Further reading
-
- Cancer Biology
- Cell Biology
-
- Cancer Biology
- Cell Biology
